3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
7
Ovarian Neoplasms
6
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Recurrence
2
Peritoneal Neoplasms
2
Lung Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Patients With Any Advanced Solid Tumors
1
Ovarian Diseases
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Mesothelioma, Malignant
1
Melanoma, Cutaneous Malignant
1
Malignant Solid Tumour
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid, Acute
1
Interventions
Gemcitabine
9
Paclitaxel
8
Carboplatin
7
atezolizumab
6
Sunitinib
5
navitoclax
4
Topotecan
4
Irinotecan
4
Docetaxel
4
Bevacizumab
4
pazopanib
3
liposomal doxorubicin
3
cobimetinib
3
Nivolumab
3
Erlotinib Hydrochloride
3
zolbetuximab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
temsirolimus
2
selicrelumab
2
plocabulin
2
envafolimab
2
darinaparsin
2
brigimadlin
2
adavosertib
2
Tablets
2
Sorafenib
2
Rifampin
2
RG7388
2
Panitumumab
2
NVP-BKM120
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Solid Tumors
×
nintedanib
×
Clear all
NCT01349296
2016-05-20
BARIS
University of Cologne
Phase 1
Completed
18 enrolled